ResearcherUniversity of MiamiActive in the last 2 years

Jonathan S. England

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6330-3688; OpenAlex author ID A5015418005. Sources: OpenAlex.

Their work

Papers: 4 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 1 paper

Papers 4

Metastatic Pancreatic Adenocarcinoma Downstaged to T0N0 with Chemotherapy and Targeted Therapy, Confirmed by Surgical Pathology: A Case Report. Last author DOI 10.1159/000539776 ↗
Pancreatic cancer presenting as bowel obstruction and role of next generation sequencing: A case report. Co-author DOI 10.1016/j.ijscr.2021.106654 ↗
Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy resp… Co-author DOI 10.7554/elife.78921 ↗
Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report. Co-author DOI 10.1101/mcs.a006108 ↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Bach Ardalan · 3 shared papers, 2021–2024 · strength 0.66
Danny Sleeman · 1 shared paper, 2024 · strength 0.24
- Paper Metastatic Pancreatic Adenocarcinoma Downstaged to T0N0 with Chemotherapy and Targeted Therapy, Confirmed by Surgical P… DOI 10.1159/000539776 ↗
Rene Hartmann · 1 shared paper, 2022 · strength 0.22
- Paper Pancreatic cancer presenting as bowel obstruction and role of next generation sequencing: A case report. DOI 10.1016/j.ijscr.2021.106654 ↗
Tiffany Alyssa Eatz · 1 shared paper, 2021 · strength 0.19
- Paper Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal ad… DOI 10.1101/mcs.a006108 ↗
Iago De Castro Silva · 1 shared paper, 2022 · strength 0.14
- Paper Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphoc… DOI 10.7554/elife.78921 ↗
Nilesh Deshpande · 1 shared paper, 2022 · strength 0.14
- Paper Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphoc… DOI 10.7554/elife.78921 ↗
Siddharth Mehra · 1 shared paper, 2022 · strength 0.14
- Paper Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphoc… DOI 10.7554/elife.78921 ↗
Prateek Sharma · 1 shared paper, 2022 · strength 0.14
- Paper Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphoc… DOI 10.7554/elife.78921 ↗
Peter J. Hosein · 1 shared paper, 2022 · strength 0.14
- Paper Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphoc… DOI 10.7554/elife.78921 ↗
Nipun B. Merchant · 1 shared paper, 2022 · strength 0.14
- Paper Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphoc… DOI 10.7554/elife.78921 ↗
Jashodeep Datta · 1 shared paper, 2022 · strength 0.14
- Paper Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphoc… DOI 10.7554/elife.78921 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.